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Abstract
Background: Pertussis toxin (PT) is an exotoxin virulence factor produced by Bordetella pertussis,
the causative agent of whooping cough. PT consists of an active subunit (S1) that ADP-ribosylates
the alpha subunit of several mammalian G proteins, and a B oligomer (S2–S5) that binds
glycoconjugate receptors on cells. PT appears to enter cells by endocytosis, and retrograde
transport through the Golgi apparatus may be important for its cytotoxicity. A previous study
demonstrated that proteolytic processing of S1 occurs after PT enters mammalian cells. We sought
to determine whether this proteolytic processing of S1 is necessary for PT cytotoxicity.
Results: Protease inhibitor studies suggested that S1 processing may involve a metalloprotease,
and processing does not involve furin, a mammalian cell protease that cleaves several other
bacterial toxins. However, inhibitor studies showed a general lack of correlation of S1 processing
with PT cellular activity. A combination of replacement, insertion and deletion mutations in the C-
terminal region of S1, as well as mass spectrometry data, suggested that the cleavage site is located
around residue 203–204, but that cleavage is not strongly sequence-dependent. Processing of S1
was abolished by each of 3 overlapping 8 residue deletions just downstream of the putative cleavage
site, but not by smaller deletions in the same region. Processing of the various mutant forms of PT
did not correlate with cellular activity of the toxin, nor with the ability of the bacteria producing
them to infect the mouse respiratory tract. In addition, S1 processing was not detected in
transfected cells expressing S1, even though S1 was fully active in these cells.
Conclusions: S1 processing is not essential for the cellular activity of PT. This distinguishes it from
the processing of various other bacterial toxins, which has been shown to be important for their
cytotoxicity. S1 processing may be mediated primarily by a metalloprotease, but the cleavage site
on S1 is not sequence-dependent and processing appears to depend on the general topology of the
protein in that region, indicating that multiple proteases may contribute to this cleavage.
Background
Pertussis toxin (PT) is a complex exotoxin and an impor-
tant virulence factor produced by Bordetella pertussis, a bac-
terial pathogen of the human respiratory tract that causes
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the disease whooping cough. PT holotoxin is a multi-sub-
unit complex with an AB5 structure [1,2]: the enzymati-
cally active A subunit (S1) is an ADP-ribosyltransferase
that modifies the alpha subunit of several heterotrimeric
G proteins (primarily Gi proteins) in mammalian cells
[3,4], and the B oligomer (S2, S3, 2 copies of S4, and S5)
binds unidentified glycoconjugate receptors on cells [5,6].
The events in the intracellular trafficking of PT between
surface binding and ADP-ribosylation of target G proteins
on the cytoplasmic side of cellular membranes are rela-
tively obscure. Electron microscopy studies and experi-
ments with inhibitors suggest that the holotoxin is
internalized by endocytosis [7-9]. Subcellular fractiona-
tion experiments and inhibition of cytotoxicity by Brefel-
din A (BFA), which disrupts the Golgi apparatus [10],
provide evidence for subsequent retrograde transport of
PT to the Golgi apparatus [7-9]. Trafficking of PT beyond
the Golgi apparatus is relatively uncharacterized, though
it has been hypothesized that further retrograde transport
of PT through the secretory pathway to the endoplasmic
reticulum (ER) occurs [11-13]. After dissociation of S1
from the holotoxin, the liberated S1 subunit is then pro-
posed to traverse the ER membrane to gain access to its
target G proteins in the cytosol [13]. Evidence supporting
this ER-to-cytosol translocation was obtained from trans-
fection studies with constructs expressing S1 with a signal
peptide for ER localization [12].
Another observation that may bear on the cell biology and
cytotoxicity of PT is that the S1 subunit appears to be pro-
teolytically processed to a lower molecular weight form
upon interaction of PT with mammalian cells [14]. This
processing was shown to be dependent upon entry of PT
into cells and seemed to involve an early endosome func-
tion. The size of the processed form of S1 (approximately
22 kDa versus 26 kDa for the full-length S1) suggested
that processing may be targeted at a protease-sensitive
loop near the C-terminus of S1 that contains primary sites
for trypsin and chymotrypsin cleavage [15]. However, evi-
dence for the location of the cellular cleavage site on S1
was not presented. In addition, a link between processing
of S1 and activity of PT in cells was not established. Prote-
olytic processing is a common theme in the activation of
bacterial toxins upon interaction with mammalian cells.
For example, anthrax toxin, diphtheria toxin, Pseudomonas
exotoxin A and shiga toxin are all activated after cleavage
by the endogenous eukaryotic protease furin [16], a sub-
tilisin-like protease residing in the secretory pathway of
eukaryotic cells [17], or by closely-related proteases [18].
Cholera toxin (CT) and Escherichia coli heat-labile toxin
(LT) A subunits are cleaved at a protease-sensitive loop to
promote maximal activity [19,20], and CT A subunit was
found to be cleaved upon interaction of CT with T84 epi-
thelial cells, by an unidentified protease [21].
In this study we extend the analysis of proteolytic process-
ing of cell-associated S1 and conclude that S1 processing
is not essential for the cellular activity of PT.
Results and discussion
Processing and fractionation of S1 in PT-treated CHO cells
In a previous study, 125I-labelled PT was used for analysis
of S1 processing in mammalian cells [14]. As an alterna-
tive to radiolabeled toxin, we analyzed detergent lysates of
cells treated with unlabeled PT to determine whether we
could detect S1 processing. Near-confluent Chinese ham-
ster ovary (CHO) cells were treated with PT (20 nM) for 4
h at 37°C, and then cells were washed, recovered by
trypsinization and lysed on ice with either Triton X-100
lysis buffer or RIPA lysis buffer. The detergent-soluble and
-insoluble fractions were then analyzed by sodium
dodecylsulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and western blotting. As shown in Fig. 1A, we were
able to detect processing of S1 by this method, with the
majority of cell-associated S1 present as the lower molec-
ular weight form (S1p, approximately 22 kDa, versus 26
kDa for full length S1). This processing event was inde-
pendent of PT enzymatic activity, since the enzymatically
inactive PT-9K/129G (PT*) was similarly processed by
CHO cells (Fig. 1B). The kinetics of S1 processing (data
not shown) were very similar to those previously reported
[14], which, along with the similar size of the processed
form, strongly suggested that we were observing the same
event as previously studied. Surprisingly, however, the
great majority (>80%) of S1 fractionated with the deter-
gent-insoluble pellet material in this assay. Triton lysis at
25°C rather than on ice increased the proportion of S1
that was solubilized, but at least half of the processed
form remained in the insoluble pellet material (Fig. 1A).
To determine whether S1 fractionation with the detergent-
insoluble material represented a potentially interesting
feature of its intracellular transport, or merely an artifact
of the lysis procedure, we added 500 ng PT to a Triton
lysate of untreated CHO cells, incubated this on ice 30
min, centrifuged to separate the mix into soluble and
insoluble fractions and analyzed these by SDS-PAGE and
western blotting. Almost all (>95%) of the S1 fractionated
to the insoluble pellet (Fig. 1C), demonstrating that S1
association with detergent-insoluble material occurs in
the lysate and is independent of PT transport within cells.
The Triton-insoluble fraction typically contains nuclei
and cytoskeletal components [22], so it is possible that
PT, or at least S1, has an affinity for one or more of these
components.
Effects of protease and cell trafficking inhibitors on S1 
processing in CHO cells
We first ruled out the possibility that furin, a protease that
cleaves several other bacterial toxins in mammalian cells,
is responsible for S1 cleavage, by finding that S1BMC Microbiology 2005, 5:7 http://www.biomedcentral.com/1471-2180/5/7
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S1 processing and detergent fractionation in CHO cells Figure 1
S1 processing and detergent fractionation in CHO cells. (A) Cells were incubated with PT (20 nM) for 4 h followed by lysis 
with RIPA or Triton X-100 (TX100) buffer on ice or at room temperature (RT). A western blot of the detergent-insoluble (I) 
and -soluble (S) fractions is shown, with bands corresponding to full length S1 or processed S1 (S1p) indicated. Lane marked C 
is PT (200 ng) loading control. (B) Western blot of Triton X-100 lysate fractions of CHO cells treated with PT or PT* (catalyt-
ically inactive mutant of PT) for 4 h. (C) Western blot of Triton X-100 lysate fractions of untreated CHO cells after addition of 
500 ng PT to the lysis mixture.
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Effect of inhibitors on S1 processing and PT activity in CHO cells Figure 2
Effect of inhibitors on S1 processing and PT activity in CHO cells. (A, B) CHO cells were preincubated with the indicated inhib-
itor before addition of PT (20 nM) and then analyzed for S1 processing as before. Western blots are shown with unprocessed 
and processed (S1p) forms of S1 indicated. Lanes marked C are PT (100–200 ng) loading controls. DMSO = dimethylsulfoxide 
(solvent control). Metalloprotease inhibitor concentrations are indicated (mM). 0 = no inhibitor. BafA1 = bafilomycin A1. (C) 
Effect of inhibitors on ADP-ribosylation of CHO cell G proteins by PT. Autoradiogram of cellular ADP-ribosylation assay after 
treatment of CHO cells with the indicated inhibitor and either PT or PT* (last lane). Radiolabeled band (approximately 41 kDa) 
corresponds presumably with Giα2 and Giα3 [9].
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processing occurs normally in furin-deficient FD11 cells
[23] (data not shown). This observation was not surpris-
ing since there are no consensus furin cleavage sites in the
S1 sequence. In order to determine the catalytic type of
protease responsible for S1 processing in CHO cells, we
preincubated CHO cells with serine, cysteine, aspartic and
metalloprotease inhibitors (following the suggestions of
Barrett [24]) before addition of PT, and studied S1
processing by these cells as before (Fig. 2). The broad spe-
cificity serine protease inhibitor 3,4-DCI did not signifi-
cantly inhibit processing (though the inhibitor was
somewhat toxic to the CHO cells and reduced the amount
of S1 recovered), and neither did the serine protease
inhibitor aprotinin (Fig. 2A). The serine protease inhibi-
tor pefabloc SC (BMB/Roche) did have a consistent inhib-
itory effect on S1 processing, with approximately 45% of
the cell-associated S1 in the unprocessed form (versus
approximately 10% on average in the absence of inhibi-
tor). Since the other serine protease inhibitors had no
effect on S1 processing, the reason for the inhibitory effect
of pefabloc SC is unclear, but may be related to its ability
to bind covalently to proteins (BMB/Roche). Neither the
aspartic protease inhibitor pepstatin nor the cysteine pro-
tease inhibitor E-64 had any significant inhibitory effect
on S1 processing (Fig. 2A) (nor did the cysteine/serine
protease inhibitor leupeptin – data not shown). However,
EDTA had a strong inhibitory effect on S1 processing by
CHO cells (Fig. 2A,B), with 56% and 74% of cell-associ-
ated S1 in the unprocessed form in the presence of 0.5
mM and 1 mM EDTA, respectively. Since the inhibitory
effect of a non-specific metal chelator such as EDTA could
be due to the cation-dependence of activity of other pro-
teases [24], we also used the metalloprotease inhibitor
1,10-phenanthroline, which has a high affinity for zinc
and is considered the most useful inhibitor for metallo-
proteases [24]. This inhibitor also had a strong inhibitory
effect on S1 processing by CHO cells (Fig. 2B), with 61%
and 63% of cell-associated S1 in the unprocessed form in
the presence of 0.5 mM and 1 mM phenanthroline,
respectively. Therefore, we conclude that the cellular pro-
tease responsible for S1 processing in CHO cells is most
likely a metalloprotease, which presumably resides in the
secretory (endocytic) pathway and the identity of which
remains to be determined. This is a novel observation in
the sense that other bacterial toxins are cleaved by cellular
proteases of the subtilisin family (such as furin) [16,23] or
by other serine proteases [21], although one report dem-
onstrated that CT activity on several different cell types
was blocked by a competitive substrate for metallopro-
teases [25], suggesting that metalloproteases may also be
involved in the cellular activity of other bacterial toxins.
However, the possibility remains that multiple proteases,
possibly of different classes, are involved in this S1
processing event.
We also determined the inhibitory activity on S1 process-
ing by CHO cells of two inhibitors of cellular trafficking
and secretion, bafilomycin A1, which inhibits vacuolar
proton ATPase and therefore prevents endosome acidifi-
cation [26], and BFA, which disrupts the Golgi apparatus
[10]. Bafilomycin A1 had a significant inhibitory effect on
S1 processing, with 51% of cell-associated S1 in the
unprocessed form (Fig. 2B), consistent with the hypothe-
sis that S1 processing occurs in the endosomal compart-
ment of CHO cells and demonstrating a role for
endosome acidification in this processing event. How-
ever, BFA had no inhibitory effect on S1 processing (Fig.
2B), consistent with previously reported results [14] and
with the hypothesis that S1 processing occurs prior to the
Golgi apparatus in the putative retrograde trafficking
pathway.
Effects of S1 processing inhibitors on cellular activity of PT
Proteolytic processing of bacterial toxins is a common
theme in their activation within mammalian cells [16],
but whether cellular processing of S1 plays a role in the
activity of PT had not been previously addressed. As a pre-
liminary investigation of this question, we sought to
determine whether the inhibitors of S1 processing by
CHO cells had any effect on the ability of PT to ADP-ribo-
sylate target G proteins in CHO cells. CHO cells were pre-
incubated with inhibitors before addition of PT (1 nM) as
before. Controls were cells to which either PT or PT*
(which has no ADP-ribosylation activity) was added in
the absence of inhibitor. Cells were recovered after 3 h,
and lysates were prepared and tested in the ADP-ribosyla-
tion assay. In this assay, active PT within cells will ADP-
ribosylate available G proteins, so that when a lysate is
prepared from these cells and used in an in vitro ADP-
ribosylation assay with PT and 32P-labelled NAD, there is
no labeling of G proteins in the lysate, since they were
already modified by the PT added to the cells. If PT activity
within cells is inhibited, then a proportion of the G pro-
teins in the lysate from these cells will be unmodified and
therefore labeled in the in vitro reaction with PT. The
assay was repeated twice and the result of one experiment
is shown in Fig. 2C. The mean percent inhibition for the
various inhibitors (in decreasing order of their inhibitory
effect) was as follows: pefabloc SC – 95%, BFA – 79%,
bafilomycin A1 – 49%, EDTA – 44%, phenanthroline –
28%, 3,4-DCI – 9%, pepstatin – 8%. Therefore there was
no strong correlation between the extent of inhibition of
S1 processing by the inhibitors and their inhibitory activ-
ity on ADP-ribosylation of G proteins by PT in CHO cells.
The cell trafficking/secretion inhibitors had a significant
inhibitory effect (BFA has previously been shown to
inhibit cellular activity of PT [7-9], presumably due to its
disruption of PT trafficking in cells, despite its lack of inhi-
bition of S1 processing), but the metalloprotease inhibi-
tors had only a mild inhibitory effect. Of the otherBMC Microbiology 2005, 5:7 http://www.biomedcentral.com/1471-2180/5/7
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protease inhibitors, pefabloc SC had the greatest inhibi-
tory effect, as it did on S1 processing, whereas pepstatin
had no significant inhibitory effect on ADP-ribosylation
(or S1 processing). To rule out an effect of the inhibitors
on the enzymatic activity of PT (independent of its cellu-
lar activity), we also performed in vitro ADP-ribosylation
assays with PT in the presence of the various inhibitors at
the concentrations used on the CHO cells. No significant
inhibitory effect was seen with any of the inhibitors (data
not shown) with the exception of 3,4-DCI, which was also
somewhat toxic to the CHO cells but did not significantly
inhibit processing of S1. Altogether, these data are incon-
clusive with regard to the hypothesis that cellular process-
ing of S1 plays a role in the ADP-ribosylation of G
proteins in CHO cells by PT.
Location of processing site on S1
We reasoned that if we could identify the precise process-
ing cleavage site on S1, then we would be able to muta-
genize this site, obtain a mutant form of S1 that was
resistant to cellular processing, and then determine
whether processing was required for cellular activity of PT.
The size of S1p compared to unprocessed S1 (approxi-
mately 22 kDa versus 26 kDa) suggested a cleavage site
close to either the N-terminus or the C-terminus of S1,
although processing at both termini was also a possibility.
Processing at the N-terminus of S1 seems unlikely in view
of the fact that the arginine at amino acid 9 (R9) is crucial
to enzymatic activity [27]. A protease-sensitive loop that
has primary sites for trypsin and chymotrypsin cleavage
[15] is located towards the C-terminus of S1 (amino acids
211–220; Fig. 3) [1]. To help define the location on S1 of
processing by CHO cells, we compared the cellular
processing of a modified form of PT containing an exten-
sion of 9 amino acids at the N-terminus of S1 (PT*-CSP/
N) to that of native PT. As shown in Fig. 4A, the processed
form of S1 in cells incubated with PT*-CSP/N was slightly
larger (approximately 1 kDa) than that of cells incubated
with PT, leading to the conclusion that processing occurs
towards the C-terminus of S1. The presence of 2 processed
forms of S1 in cells incubated with PT*-CSP/N presuma-
bly reflects some additional processing of the N-terminal
extension, but since each of these forms is larger than that
of S1p from native PT, the conclusion is the same. Fig. 4B
shows that the major trypsin-digested fragment of S1 is
slightly larger than S1p from cellular processing of PT,
suggesting that the site on S1 of cellular processing is close
to the protease-sensitive loop, but is N-terminal to the
trypsin cleavage site (at R218). However, we cannot rule
out the possibility of intracellular modification of S1 that
would alter its migration on SDS-PAGE gels and compli-
cate the interpretation of this experiment.
We performed extensive site-specific mutagenesis in the
region between M202 and R218 of S1 in an attempt to
obtain a mutant form of PT that was no longer processed
in mammalian cells. However, we were unable to obtain
such a mutant by this approach – almost all PT mutants
were processed normally, including those with changes at
the primary cleavage sites for trypsin (R218A) and chymo-
trypsin (W215A) (Fig. 5A). Certain changes at residue
A203 (A203D, A203R) resulted in very low levels (<1%)
of PT secretion by B. pertussis (data not shown) so that we
were unable to determine whether processing was
affected. However, other changes at this residue (A203G,
A203S, A203V) had no effect on PT secretion, processing
or activity (data not shown). In an attempt to locate the
processing site, we constructed mutant forms of PT with
deletions of various stretches of residues in this region.
Each of 2 adjacent deletions of 8 residues (∆203–210,
∆211–218; Fig. 3) resulted in the complete loss of S1
processing in CHO cells (as far as could be determined by
western blotting – Fig. 5A), and the same was true of the
overlapping 8 residue deletion ∆207–214 (data not
shown), strongly suggesting that the processing site is
located in this region. However, smaller overlapping dele-
tions of 4 or 5 residues in this region did not disrupt S1
processing (Fig. 5 and data not shown), indicating that no
particular sequence in this region served as a specific
cleavage site for the processing event. In further support of
this idea, 2 PT constructs in which residues 210–218 of S1
were replaced by random amino acid sequence (210–218/
R1 and 210–218/R2) were both processed normally (Fig.
5B). Equivalent replacement of residues 203–210 abro-
gated assembly and secretion of PT by B. pertussis, so we
could not make the same assessment for this region.
However, two lines of evidence suggested that the process-
ing site may be located in the region of residue A203. First,
a PT construct (I-205–206) with an insertion of 8 amino
acids between residues Q205 and A206 in S1 was
processed to the same size S1p as wild type PT (Fig. 5A),
indicating that the processing site was upstream of the
insertion (although it may have been within the inser-
tion). Second, mass spectrometry analysis of the proc-
essed and unprocessed forms of S1 in lysates from PT-
treated CHO cells identified a difference in mass between
S1 and S1p (3577.4) most closely corresponding to the
theoretical mass of a peptide from R204 to the C-terminus
of S1 (3603.9) (data not shown). However, as mentioned
above, substitutions at A203 either did not affect process-
ing of S1 or greatly reduced secretion of PT, and substitu-
tions at M202 and R204 also did not affect S1 processing
(data not shown), so we were unable to verify this puta-
tive cleavage site by mutagenesis. It is also possible that
the major processing site is further downstream (within
the 211–220 loop region for example) with subsequent
additional cleavage occurring during cell lysis, resulting in
the apparent size of S1p.BMC Microbiology 2005, 5:7 http://www.biomedcentral.com/1471-2180/5/7
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Effect of processing site mutations on PT activity
We determined the effect of several of these deletion and
replacement mutations on PT activity using the ADP-ribo-
sylation assay. Cells were incubated with the purified PT
construct (2 nM) for 3 h to determine cellular activity. As
shown in Fig. 6A, all mutant constructs retained signifi-
cant activity, relative to the inactive mutant PT*. The two
deletion mutants that were not processed in cells were
analyzed further and were found to possess 88.5%
(∆203–210) and 78.1% (∆211–218) of wild type PT cel-
lular activity (Fig. 6B). The in vitro activity of these con-
structs was also assayed, using a fusion of GST with the C-
terminal 20 amino acids of human Giα3 (GST-αC20) as
the substrate, with the finding that the ∆203–210 mutant
possessed 100% of wild type PT activity while the ∆211–
218 mutant had a 26.5% reduction in activity (Fig. 6B).
We also found that the 210–218 replacement mutants
retained full cellular activity (Fig. 6C). Together these data
demonstrate that S1 processing is not essential for PT cel-
lular activity, since the mutants in which processing was
apparently abolished retained significant activity. How-
ever, this conclusion must remain tentative in the absence
of a single substitution mutant that is unprocessed, which
would be the best reagent to answer this question. A large
deletion of eight amino acid residues may affect other PT-
associated properties or may mask the effects of the loss of
processing. The stability of these mutant forms of PT may
have been altered, though apparently not significantly
reduced from the processing assay data (Fig. 5). It is also
possible that the number of PT molecules necessary for
full activity is low enough to be undetectable in the
processing western blot assay. In previous studies, limited
trypsin cleavage of PT increased its activation in vitro [15],
indicating that S1 processing may play a role in activity,
and domains on S1 for interaction with target proteins
and enzymatic activity were found to lie within the N-ter-
minal 204 amino acids [28], so the processed form of S1
should retain these functions.
We also tested several strains expressing mutant PT con-
structs in our mouse infection model of B. pertussis viru-
lence [29], and none of these strains was significantly
defective in colonization compared to the parental wild
type strain (data not shown). Although these data suggest
Diagram of the S1 protein and the putative cleavage site Figure 3
Diagram of the S1 protein and the putative cleavage site. The region of investigation between A200 and E221 is highlighted and 
details of some of the mutant constructs are shown. The line with a ∆ symbol indicates the deleted amino acids.
-ACMARQAESSEAMAAWSERAGE-
S1 catalytic domain 11 8 0 235
flexible loop
200 205 210 215 220
* *
∆
∆
∆ ∆ ∆ ∆203-210
∆ ∆ ∆ ∆211-218
-QSRVGTLAL-
-PVGAVSIVG-
210-218/R1
210-218/R2BMC Microbiology 2005, 5:7 http://www.biomedcentral.com/1471-2180/5/7
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that S1 processing is not essential for the virulence of B.
pertussis, it is possible that S1 could be processed in vivo
by alternative proteases absent from CHO cells.
Processing in stable CHO cell transfectants expressing S1
Previously we constructed stable CHO cell transfectants
expressing S1 either with a signal peptide (for ER localiza-
tion) or without one (for cytoplasmic localization), and
showed that S1 fully ADP-ribosylated target G proteins in
each transfectant [12]. In that study we did not observe
significant processing of S1 in whole cell lysates of these
transfectants, but we re-examined this issue using Triton
X-100 lysis of transfectants and western blotting of the
insoluble pellet material. As seen in Fig. 7A, there was no
detectable processing of S1 to S1p in either transfectant.
Exogenous addition of PT to these cells resulted in EDTA-
inhibitable processing of S1 to S1p (Fig. 7B), demonstrat-
ing that S1 expression and activity in the transfectants did
not prevent S1 processing of exogenously added PT,
though the level of processing in the S1+SP transfectant
was apparently quite low.
The data from these transfectants do not rule out the pos-
sibility that S1 processing may contribute to the traffick-
ing of PT to the ER. However, the data are consistent with
the idea that S1 processing is not essential for its activity
in mammalian cells, and therefore that translocation of
the full-length S1 across the ER membrane occurs. This
would distinguish PT from several other bacterial toxins
of similar subunit structure, such as cholera toxin, heat-
labile toxin and shiga toxin, for which processing of the A
subunit is apparently important for cellular activity [16].
The difference may be in the association of the A subunit
with the B oligomer. The other toxin A subunits have a rel-
atively long helix that protrudes through a central pore in
the B oligomer [30], and cleavage of the A subunit is
required to release the enzymatic domain from this com-
plex. S1 has a relatively short helix associated with the B
oligomer [1], and therefore cleavage may be unnecessary
for its release from the holotoxin complex in the ER, or
whichever compartment translocation occurs from.
Conclusions
In this study we have further characterized the cellular
processing of the S1 subunit after PT interacts with mam-
malian cells. Our major conclusion is that this processing
event is not essential for PT activity in mammalian cells,
based on several lines of evidence: (1) protease inhibitor
studies showed a general lack of correlation between S1
processing and PT cellular activity; (2) mutant forms of PT
in which S1 processing was apparently abolished retained
significant (>75% of wild type) cellular activity; and (3)
no S1 processing was apparent in transfected cells express-
ing active S1. Although we have not definitively ruled out
Localization of the processing site on S1 Figure 4
Localization of the processing site on S1. (A) CHO cells were incubated with PT or PT*-CSP/N (PT*/N) for 4 h and analyzed 
for S1 processing as before. Western blots are shown of the processing samples (proc) or purified protein loading controls 
(C). (B) Western blot comparing S1p after processing of PT in CHO cells (proc) or trypsin cleavage (tryp) of PT (200 or 100 
ng).
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a contribution of S1 processing to the cellular activity of
PT due to the imperfect nature of our unprocessed
mutants, it is possible that the processing event is com-
pletely unrelated to PT cytotoxicity and instead is an irrel-
evant activity occurring, possibly in lysosomes, on the
large majority of the intracellular pool of PT molecules
that do not enter the putative retrograde transport path-
way to the ER and then on to the cytosolic target proteins.
Methods
Bacterial strains and growth conditions
The B. pertussis strain used in this study was a streptomy-
cin- and nalidixic acid-resistant derivative of W28 (Well-
come). The PT9K/129G (PT*) derivative of this strain was
constructed as previously described [27]. The other PT
mutant derivatives used in this study were constructed as
described below. B. pertussis was grown on Bordet-Gengou
Processing of mutant PT proteins in CHO cells Figure 5
Processing of mutant PT proteins in CHO cells. (A) Western blot showing purified protein (lanes marked [C]) or processing of 
S1 (lanes marked [proc]) after addition of various mutant PT proteins (20 nM) to CHO cells. (B) Western blot showing 
processing of S1 (lanes marked [proc]) after addition of the 210–218/R replacement mutant PT proteins or PT and PT* con-
trols to CHO cells.
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ADP-ribosylation assay of mutant PT constructs Figure 6
ADP-ribosylation assay of mutant PT constructs. (A) Autoradiogram of cellular ADP-ribosylation assay after treatment of 
CHO cells with the indicated PT protein. The upper radiolabeled band (approximately 41 kDa) corresponds presumably with 
Giα2 and Giα3, while the lower band is PT-independent endogenously labeled band often seen in this assay with CHO cell 
lysates [9]. (B) Graphed data showing the mean (n = 3) cellular activity of the 2 deletion constructs that are not processed 
(activity of wild type PT was set at 100%) and the in vitro ADP-ribosylation activity of the same proteins. (C) Autoradiogram of 
cellular ADP-ribosylation assay after treatment of CHO cells with the indicated PT protein, demonstrating the retention of 
activity of the replacement mutant PT constructs.
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agar (Difco) plates containing 15% defibrinated sheep
blood and the following antibiotics at the indicated con-
centrations where necessary: streptomycin 400 µg ml-1,
nalidixic acid 20 µg ml-1, gentamicin 10 µg ml-1; or in
Stainer-Scholte liquid medium [31] containing heptakis-
dimethylcyclodextrin (Sigma). Escherichia coli strains used
were DH10B [32] for standard cloning experiments and
S17.1 [33] for conjugation with B. pertussis, and these were
grown on LB agar plates containing 10 µg ml-1gentamicin
where necessary or in LB broth containing 100 µg ml-
1ampicillin.
Plasmid and strain construction
Plasmid pJ-PT was obtained by subcloning a 2.3 kb EcoRI-
BsrGI fragment (containing the PT S1 and S2 genes) into
EcoRI/Acc65I-digested allelic exchange vector plasmid
pJHC1 [34]. Mutations were engineered into the S1
sequence of this plasmid, which was confirmed by DNA
sequencing, transformed into E. coli S17.1 and introduced
into the B. pertussis chromosome by conjugation and
allelic exchange as described previously [35]. Deletion,
insertion and substitution mutations were constructed by
overlap extension PCR [36], and the 210–218/R1 and R2
replacement mutations were constructed by using a
degenerate oligonucleotide (CARBON 1097; 5'-
GATAAGAGCTCCVNNVNNVNNVNNVNNVNNVNNVN-
NVNNGCCGGCGAGGCCTCGCC-3' where V = G, A, or C
and N = any nucleotide) which was allowed to anneal,
extended with DNA polymerase Klenow fragment,
digested with SacI and BglI and inserted into SacI- and
BglI-digested pJ-PT. The GST-αC20 construct was
obtained by inserting annealed complementary oligonu-
cleotides (encoding the C-terminal 20 amino acids of
human Giα3) into the plasmid pGEX-2T (Pharmacia) to
derive pGEX-αC20. The PT*-CSP/N construct was
obtained as previously described [11].
Western blotting
Samples were run on 12% SDS-PAGE gels and transferred
to nitrocellulose filters. To detect S1, blocked filters were
incubated with S1-specific monoclonal antibody X2X5 or
1C7, followed by peroxidase conjugated anti-mouse IgG
secondary antibody (Amersham). Blots were developed
using ECL Plus (Amersham) and exposed to X-ray film.
Protein purification
PT and mutant derivatives were prepared from B. pertussis
culture supernatants by the fetuin affinity method of
Kimura et al. [37], resuspended in PBS and stored at -
80°C until use. The protein concentration was deter-
mined by BCA assay (Pierce). GST-αC20 protein was puri-
fied from a culture of E. coli DH10B containing the
plasmid pGEX-αC20. For induction of the fusion protein,
the strain was grown in LB to A600 1.0 and then IPTG was
added to a concentration of 0.5 mM. 2 h after IPTG addi-
tion, cells were centrifuged, lysed in BPER lysis reagent
S1 processing in CHO cell transfectants expressing S1 Figure 7
S1 processing in CHO cell transfectants expressing S1. (A) Western blot showing lack of processing of endogenous S1 in trans-
fectants expressing S1 in the cytosol (S1-SP) or in the ER (S1+SP). (B) Western blot showing EDTA-inhibitable processing of S1 
after exogenous addition of purified PT (20 nM) to these transfectants.
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(Pierce), cleared by centrifugation, and passed through a
GSTrap column (Amersham-Pharmacia). Fusion protein
was eluted in reduced glutathione buffer, dialyzed against
PBS and analyzed by SDS-PAGE and BCA assay (Pierce) to
determine protein concentration.
Cell lysis and fractionation
CHO cells were grown in 6-well plates to near confluency
and then PT was added and incubated for the indicated
times at 37°C. Cells were then collected by trypsinization,
washed in PBS, resuspended in 50–100 µl of either NET/
Triton lysis buffer (150 mM NaCl, 5 mM EDTA, 50 mM
Tris, pH 7.4, 0.01% NaN3, and 0.5% Triton X-100) or
RIPA buffer (10 mM Tris, pH 7.4, 0.1% SDS, 1% sodium
deoxycholate, 1% NP-40, 150 mM NaCl) and incubated
30 min on ice. The lysate was then centrifuged 15 min at
13,000 rpm at 4°C in a microfuge, the supernatant was
removed to a fresh tube and the pellet was resuspended in
sample buffer. Samples were boiled 5 min and loaded
onto an SDS-PAGE gel.
Inhibitors
Inhibitors were added to CHO cells 30 min prior to the
addition of PT. For protease inhibitors we followed the
suggestions of Barrett [24] to determine the catalytic type
of protease involved. Protease inhibitors (BMB/Roche)
and concentrations used were: aprotinin (0.15 µM), 3,4-
dichloroisocoumarin (3,4-DCI, 1 mM) and 4-(2-aminoe-
thyl)-benzenesulfonyl-fluoride, hydrochloride (pefabloc
SC, 1 mM) for inhibition of serine proteases; trans-epoxy-
succinyl-L-leucylamido(4-guanidino)butane (E-64, 1
mM) and leupeptin (1 µM) for inhibition of cysteine pro-
teases; pepstatin (1 µM) for inhibition of aspartic pro-
teases; and EDTA (0.5–1 mM) and 1,10-phenanthroline
(0.5–1 mM) for inhibition of metalloproteases. Other
inhibitors used were BFA (Sigma, 5 µg/ml) and bafilomy-
cin A1 (ICN, 0.5 µM). After SDS-PAGE and western blot-
ting of samples, band intensities were measured by
densitometry and used to calculate the extent of inhibi-
tion of S1 processing.
Trypsin digestion of PT
PT (100 or 200 ng) was digested with trypsin (Sigma) in a
volume of 20 µl at room temperature for 1 h in 50 mM
Tris, pH 8, and 2 mM CaCl2. Trypsin was present at 70 µg/
ml. Sample buffer was added and the samples were then
boiled 5 min before loading onto an SDS-PAGE gel.
Western blotting
Samples were run on 12% SDS-PAGE gels and transferred
to nitrocellulose filters. To detect S1, blocked filters were
incubated with S1-specific monoclonal antibody X2X5
(3) (a generous gift from Drusilla Burns) or 3CX4, fol-
lowed by peroxidase conjugated anti-mouse IgG
secondary antibody (Amersham). Blots were developed
using ECL Plus (Amersham) and exposed to X-ray film.
ADP-ribosyltransferase assays
To determine the cellular activity of PT samples, PT (0.5–
2 nM) was added to near confluent CHO cells in 12-well
culture plates, and after 3 h at 37°C cells were recovered
from plates, washed in PBS and lysed in NET/Triton lysis
buffer 30 min on ice. The lysate was then centrifuged 15
min at 13,000 rpm at 4°C and the supernatant was stored
at -20°C until the assay. The ADP-ribosylation assay con-
tained, in 25 µl, 0.1 M Tris, pH 7.5, 20 mM dithiothreitol
(DTT), 0.5 mM ATP, 1 µM 32P-NAD (specific activity 30
Ci/mmol; NEN), 10 ng PT, and an aliquot of the lysate
sample. For assessment of in vitro enzymatic activity of PT
samples by ADP-ribosylation assay, reactions contained,
in 25 µl, 0.1 M Tris, pH 7.5, 20 mM DTT, 0.5 mM ATP, 1
µM 32P-NAD (specific activity 30 Ci/mmol; NEN), 10–50
ng PT, and 0.5 µg GST-αC20 protein as substrate. The mix-
ture was incubated 90 min at room temperature, sample
buffer was added, and the sample was boiled 5 min and
loaded onto 15% SDS-PAGE gels. After electrophoresis,
gels were fixed, dried and exposed to X-ray film. Band
intensities were measured by densitometry and used to
calculate the extent of ADP-ribosylation of target proteins.
Mass spectrometry analysis
CHO cells were incubated overnight with PT and then
lysates were made using Triton X-100 buffer at room tem-
perature (to maximize the proportion of S1 in the soluble
fraction). Purified 1C7 monoclonal antibody was allowed
to bind to a PS10 chip (Ciphergen Biosystems) for 2 h at
room temperature, which was then washed with PBS. The
CHO cell lysates (soluble fraction) were diluted 1:1 with
PBS and 100 µl of each lysate was added to a spot on the
chip and incubated at 5°C for 4 days. The chip was
washed 3 times with PBS containing 0.1% Triton X-100, 3
times with PBS, and twice with 5 mM HEPES (pH 7.0).
After the chip was air-dried, matrix (Sinapinic acid) was
added to each spot and allowed to dry. Matrix-assisted
laser desorption/ionization-time of flight (MALDI-TOF)
mass spectrometry analysis of these samples was per-
formed in a model PBS-II machine (Ciphergen).
Mouse infection
Six-week-old female BALB/c mice (Harlan) were used for
infection experiments. Bacterial inocula were prepared
and intranasal inoculation of mice was performed as pre-
viously described [29]. Seven days after inoculation, mice
were sacrificed by carbon dioxide inhalation and the res-
piratory tract (trachea + lungs) was removed, homoge-
nized in 2 ml PBS, and dilutions were plated on BG-blood
agar plates containing streptomycin to determine the
number of colony forming units (CFU) per respiratory
tract.BMC Microbiology 2005, 5:7 http://www.biomedcentral.com/1471-2180/5/7
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